吡格列酮对非酒精性脂肪肝的疗效观察

向阳; 叶家润; 李新萍

吡格列酮对非酒精性脂肪肝的疗效观察

1. 景德镇市第三人民医院内二科
2. 景德镇市第三人民医院CT室
3. 景德镇市第三人民医院妇产科

详细信息

中图分类号: R575.5
计量
- 文章访问数: 1988
- HTML全文浏览量: 14
- PDF下载量: 892
- 被引次数: 0
出版历程
- 出版日期: 2007-06-20

Safety and effectiveness of pioglitazone in the treatment of non-alcoholic fatty liver disease

摘要

摘要: 目的寻找一安全有效的治疗非酒精性脂肪性肝病的方法。方法将非酒精性脂肪性肝病患者43例随机分组,吡格列酮组22例（n=22）,对照组21例（n=21）,比较两组疗效（观察ALT,GGT,TG,HOMA-IR,BMI等指标）。结果3个月时,两组的观察指标均有改善,虽治疗组更明显,但无显著差异（P>0.05）,6个月时,ALT,GGT,TG,HOMA-IR及疗效,治疗组与对比组比较,疗效有显著差异（19/22,11/21,P<0.05）。结论胰岛素增敏剂（吡格列酮）治疗NAFLD,安全、有效,值得临床推广应用。
- 脂肪肝,非酒精性 /
- 胰岛素抵抗 /
- 吡格列酮
Abstract: Objective To find out a safe and effective treatment of non-alcoholic fatty liver disease (NAFLD) ;Methods 43 cases of NAFLD were randomized divided into tow group;pioglitazone group (n=22) and control group (n=21) , ALT, GGT, TG, HOMA-IR, BMI were compared between the two group.Results At the end of the 3rd month, the parameters were all improved, but have no statistical difference. (P>0.05) ;At the end of the 6th months, ALT, GGT, TG, HOMA-IR and effectiveness in pioglitazone group were much better than that in the control;the differences were significant (P<0.05) .Conclusion Pioglitazone is safe and effective in the treatment of NAFLD.
- fatty liver /
- non-alcoholic /
- insulin resistance

HTML全文

参考文献(12)

[1]丁效蕙, 赵景民.非酒精性脂肪性肝炎的发病机制及治疗的研究进展[J].世界华人消化杂志, 2005, 13∶371-375.

[2]Marchesini G, Brizi M, Biachi G, et al.Nonalcoholic fatty liver dis-ease:a feature of the metabolic syndrome[J].Diabetes, 2001, 50 (8) ∶1844-1850.

[3]Yoon D, Lee SH, Park HS, et al.Hypoadiponectinemia and insulin-resistance are associated with nonalcoholic fatty liver disease[J].Ko-rean Med Sci, 2005, 20∶421-426.

[4]中华医学会.肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪肝病诊断标准[J].中华肝脏病杂志, 2003, 1∶71.

[5]Day CP.Non-alcoholic fatty liver disease:current concepts andmanagement strategies[J].Clin Med, 2006, 6∶19-25.

[6]范建高.非酒精性脂肪肝的临床流行病学研究[J].中华消化杂志, 2002, 22∶106-107.

[7]Donati G, Stagni B, Piscaglia F, et al.Increased prevalence of fattyliver in arteria hypertensive with normal liver enzymes:role of insulinresistance[J].Gut, 2004, 53 (7) ∶923-924.

[8]Day CP, James OF.Steatohepatitis:a tale of two“hits”?[J].Gas-troenterology, 1998, 114∶842-845.

[9]张冬梅, 张桂英.改善胰岛素抵抗药物治疗大鼠非酒精性脂肪肝病的实验研究[J].中华医学杂志, 2006, 18∶1279-1283.

[10]王俊宏, 宋基中.罗格列酮在糖调节受损合并非酒精性脂肪肝病中的应用体会[J].中国医师杂志, 2006, 1∶122-123.

[11]蒙碧辉, 梁世坤.国产罗格列酮对实验性鼠肝脂肪变性的保护作用[J].中华消化杂志, 2003, 12∶718-722.

[12]Sanyal AJ, Mofrad PS, Contos MJ, et al.Apilot study of vitamin Eversus vitamin E and pioglitazone for the treatment of nonalcoholicsteatohepatitis[J].Clin Gastronenterol hepatol, 2004, 2∶1107-1015.

施引文献

资源附件(0)

访问统计